Brukinsa receives FDA accelerated approval for marginal zone lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Brukinsa (zanubrutinib) has received FDA accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login